Adamis Pharmaceuticals (ADMP) Stock Price
Adamis Pharmaceuticals Price
Revenue has compounded at 5.8% per year over the past 19 years to 4.76 M USD. Adamis Pharmaceuticals's net margin stands at -550.9%, down from -258.6% several years earlier. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus.
Adamis Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Adamis Pharmaceuticals business model & stock analysis
Frequently asked questions about Adamis Pharmaceuticals
Adamis Pharmaceuticals Corp is a company with a business model focused on the development and commercialization of specialty pharmaceutical products. They aim to provide innovative and cost-effective treatment options for various medical conditions, including respiratory disease, allergy, and opioid overdose. Adamis Pharmaceuticals Corp seeks to leverage their expertise in drug delivery systems to develop and improve existing medications. With a commitment to meeting unmet medical needs, they strive to enhance patient outcomes and provide value to healthcare professionals and consumers alike.
Adamis Pharmaceuticals Corp is primarily active in the healthcare and pharmaceutical industries.
Adamis Pharmaceuticals Corp faces competition from several companies in the market. Some of its main competitors include Teva Pharmaceutical Industries Ltd., Mylan N.V., and GlaxoSmithKline plc. These companies also operate in the pharmaceutical industry, offering similar products and services. It is essential for Adamis Pharmaceuticals Corp to stay competitive by constantly innovating, developing new drugs, and maintaining high product quality. By closely monitoring its competitors and adapting its strategies accordingly, Adamis Pharmaceuticals Corp can strive to achieve a dominant position in the market and continue delivering value to its customers and stakeholders.
Adamis Pharmaceuticals Corp is a pharmaceutical company specializing in the development and commercialization of therapeutic products. Established in 2006, the company primarily focuses on developing treatments for respiratory disease, allergies, and opioid overdose. Adamis Pharmaceuticals Corp is recognized for its innovation and dedication in providing effective healthcare solutions to patients. With a strong portfolio of products and ongoing research and development efforts, the company strives to improve the lives of individuals worldwide. Adamis Pharmaceuticals Corp continues to uphold its commitment to delivering high-quality pharmaceuticals and is a prominent player in the healthcare industry.
Adamis Pharmaceuticals Corp has achieved several significant milestones. One notable accomplishment is the FDA approval of their flagship product, Symjepi, which is an epinephrine injection for the emergency treatment of allergic reactions. Additionally, the company has successfully launched other pharmaceutical products in the market, such as ZIMHI for opioid overdose and Tempol for COVID-19 treatment. Adamis Pharmaceuticals Corp has also established strategic partnerships and collaborations to expand their product pipeline and improve patient care. These achievements demonstrate the company's commitment to innovation and their dedication to addressing critical medical needs.
Adamis Pharmaceuticals Corp is primarily present in the United States.
Adamis Pharmaceuticals Corp represents a strong dedication to delivering innovative and high-quality healthcare solutions. The company's core values revolve around putting patients first and striving for excellence in all areas of operation. Adamis Pharmaceuticals Corp is committed to providing accessible and affordable medications to improve the lives of individuals worldwide. With a focus on constantly developing and advancing pharmaceutical products, the company aims to make a positive impact on the healthcare industry. By prioritizing innovation, quality, and patient-centered care, Adamis Pharmaceuticals Corp strives to establish itself as a trusted and reliable partner in the pharmaceutical market.
6 analysts currently rate the Adamis Pharmaceuticals stock: 0 recommend buying, 3 holding and 3 selling.
The Adamis Pharmaceuticals share (ADMP) is listed on 5 stock exchanges, including: NASDAQ (ADMP), London (0A4X.L), Frankfurt (CY3B.F), München (CY3B.MU), Düsseldorf (CY3B.DU).
Adamis Pharmaceuticals Corp is a US pharmaceutical company specializing in the development and marketing of innovative medications and biological therapies. The company operates in several divisions, including allergy and immunology products, pulmonology products, oncology products, and veterinary products. The company's business model includes partnerships and licensing agreements with other biopharmaceutical companies, as well as targeted marketing strategies and the use of modern technologies and digital tools to promote their products and services. The goal of the company is to expand its position in the biopharmaceutical market through strong partnerships and a targeted marketing strategy.
The revenue cannot currently be calculated for Adamis Pharmaceuticals.
The profit cannot currently be calculated for Adamis Pharmaceuticals.
The P/E ratio cannot be calculated for Adamis Pharmaceuticals at the moment.
The P/S cannot be calculated for Adamis Pharmaceuticals currently.
The Eulerpool Quality Score for Adamis Pharmaceuticals is 3/10.
The ISIN of Adamis Pharmaceuticals is US00547W2089. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Adamis Pharmaceuticals is A1XA2F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Adamis Pharmaceuticals is ADMP. The ticker symbol is used to trade Adamis Pharmaceuticals shares on the stock exchange.
Adamis Pharmaceuticals stock
Adamis Pharmaceuticals Peer Group
Adamis Pharmaceuticals Ticker
All fundamentals and in-depth analysis of Adamis Pharmaceuticals
Our stock analysis for Adamis Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adamis Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.